07:24 AM EDT, 03/25/2026 (MT Newswires) -- Maze Therapeutics ( MAZE ) reported a Q4 net loss Wednesday of $0.65 per diluted share, narrower than a loss of $18.32 a year earlier.

Analysts surveyed by FactSet expected a loss of $0.72.

As of the end of 2025, the company had cash, cash equivalents and marketable securities of $360 million, which it said would be sufficient to fund operations into 2028.

Maze Therapeutics ( MAZE ) shares were up 10% in premarket activity.